Post-marketing safety signals of Wilson's disease therapies: evidence from FAERS and VigiBase - PubMed
14 hours ago
- #FAERS
- #Wilson’s disease
- #Pharmacovigilance
- Study focuses on post-marketing safety signals of Wilson's disease therapies using FAERS and VigiBase databases.
- Ethics approval was not required as the study used anonymized data from public pharmacovigilance databases.
- No conflicts of interest declared by the authors.
- Key therapies mentioned include D-penicillamine and Trientine.
- References highlight the history, clinical guidelines, and quality of life aspects of Wilson's disease.